Use of glycyrrhizin or a pharmaceutically acceptable salt thereof in the preparation of a medicament for preventing, alleviating and / or treating chronic pain after sepsis
Patent Information
- Application Number
- CN202611109592.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-07-24
- Publication Date
- 2026-09-15
Smart Images

Figure CN122745178A_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the field of biomedicine and neuroimmunotherapy technology, specifically relating to a new pharmaceutical use of glycyrrhizic acid or a pharmaceutically acceptable salt thereof, particularly its use in the preparation of medicaments for the prevention, relief and / or treatment of chronic pain following sepsis, as well as pharmaceutical compositions and formulations based on this use. Background Technology
[0002] Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to infection. Although the short-term mortality rate of sepsis has been effectively controlled thanks to advancements in life support technologies and precision anti-infective therapies, the long-term prognosis for surviving patients remains concerning. Epidemiological studies show that at least one-third of sepsis patients experience persistent pain for 6 months to 1 year after discharge from the ICU.
[0003] Chronic pain, a core component of post-intensive care syndrome (PIS), significantly reduces patients' quality of life and is significantly associated with neuropsychiatric symptoms such as anxiety, depression, and post-traumatic stress disorder. It is also an independent risk factor for mortality and readmission rates in sepsis patients. Current treatments for chronic pain typically involve: mild to moderate cases can use nonsteroidal anti-inflammatory drugs (NSAIDs) (with attention to renal function); gabapentin / pregabalin is the first-line treatment for neuropathic pain; and severe cases require short-term, standardized use of opioids. However, these medications can produce significant side effects.
[0004] Glycyrrhizic acid is the core active ingredient of licorice (Glycyrrhiza uralensis) and is known to possess anti-inflammatory, antiviral, and immunomodulatory pharmacological effects. As an inhibitor of HMGB1, glycyrrhizic acid has been shown to exert a protective effect against organ damage such as sepsis-related acute kidney injury and acute lung injury. Furthermore, studies have reported that glycyrrhetinic acid (aglycone of glycyrrhizic acid) derivatives can inhibit tachykinin receptor activation and hyperalgesia. Glycyrrhizic acid has also been used to prepare hydrogel formulations for treating compressive neuropathic pain and as a component in compositions for treating neuropathic pain.
[0005] Therefore, how to intervene in the persistent neuroimmune remodeling process after sepsis recovery and how to develop novel drug applications to improve persistent chronic pain after sepsis remain pressing technical problems in this field. This invention proposes a new solution to these technical problems. Currently, there are no reports on the use of glycyrrhizic acid alone for the prevention and / or treatment of chronic pain after sepsis. Summary of the Invention
[0006] The technical problem to be solved by the present invention is to provide the application of glycyrrhizic acid in the preparation of drugs for the prevention and / or treatment of chronic pain after sepsis. The present invention addresses the following shortcomings of the prior art: (1) lack of specific therapeutic drugs for chronic pain after sepsis; (2) the analgesic use of glycyrrhizic acid is limited to preliminary exploration of neuropathic pain and inflammatory pain, and has not yet covered the specific indication of chronic pain after sepsis; (3) the specific molecular mechanism by which glycyrrhizic acid relieves chronic pain after sepsis has not been elucidated.
[0007] This invention provides the use of glycyrrhizic acid or a pharmaceutically acceptable salt thereof in the preparation of medicaments for the prevention, relief and / or treatment of chronic pain following sepsis.
[0008] The core technical solution of this invention is to use glycyrrhizic acid or its pharmaceutically acceptable salts for chronic pain after sepsis, especially for mechanical hyperalgesia and / or thermal hyperalgesia occurring after the acute phase of sepsis or in a sepsis-surviving state. The drug increases the pain threshold by inhibiting the expression or release of HMGB1 associated with DRG macrophages, reducing the activation of the HMGB1 / TLR4 / NF-κB signaling pathway, and subsequently downregulating the expression and / or functional activity of TRPV1 in DRG primary sensory neurons. This invention is the first to discover that persistent chronic pain after sepsis is not solely due to acute inflammation, but is closely related to persistent neuroimmune remodeling in the DRG region after infection recovery. In this process, DRG macrophages are continuously activated, promoting HMGB1 release and activating the TLR4 / NF-κB / TRPV1 signaling network, causing persistent pain sensitization. Glycyrrhizic acid can effectively inhibit these abnormal signals, thereby improving chronic pain after sepsis, such as... Figure 7 As shown.
[0009] The structural formula of glycyrrhizic acid is shown below:
[0010] .
[0011] Furthermore, the pharmaceutically acceptable salts include, but are not limited to, diammonium glycyrrhizate, monoammonium glycyrrhizate, sodium glycyrrhizate, potassium glycyrrhizate, or any combination thereof.
[0012] The structural formula of the diammonium glycyrrhizate is shown below:
[0013] .
[0014] The structural formula of the glycyrrhizic acid monoammonium is shown below:
[0015] .
[0016] The structural formula of the sodium glycyrrhizate salt is shown below:
[0017] .
[0018] The structural formula of the potassium glycyrrhizate salt is shown below:
[0019] .
[0020] In a preferred embodiment, the drug is suitable for persistent pain after the acute phase of sepsis, after infection control, after sepsis treatment, after discharge from the ICU, or in the sepsis survivor state; more preferably, it is suitable for pain with a primary phenotype of reduced mechanical withdrawal threshold, shortened hot plate reaction latency, and / or shortened hot tail flick reaction latency.
[0021] In a preferred embodiment, the post-septic chronic pain includes mechanical hyperalgesia and / or thermal hyperalgesia.
[0022] In a preferred embodiment, the drug is used to reduce the expression levels of HMGB1, TLR4, phosphorylated NF-κB, and / or TRPV1 in the dorsal root ganglion.
[0023] In a preferred embodiment, the drug is used to reduce the expression or functional activity of TRPV1 in primary sensory neurons of the dorsal root ganglion.
[0024] In a preferred embodiment, the drug is used to inhibit the activation of dorsal root ganglion macrophages and / or inhibit the expression, nucleocytoplasmic translocation, or extracellular release of HMGB1 from macrophages.
[0025] In a preferred embodiment, the drug is administered via at least one of the following methods: intraperitoneal injection, intravenous injection, intrathecal injection, oral administration, and transdermal administration.
[0026] The present invention also provides a pharmaceutical composition for preventing, relieving and / or treating chronic pain following sepsis, the pharmaceutical composition comprising an effective amount of glycyrrhizic acid or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients.
[0027] In a preferred embodiment, the excipients are selected from one or more of the following: solvents, isotonic adjusters, pH adjusters, buffers, stabilizers, antioxidants, solubilizers, surfactants, fillers, disintegrants, binders, lubricants, penetration enhancers, or preservatives.
[0028] The present invention also provides the use of a pharmaceutical composition in the preparation of a medicament for reducing the activation level of the HMGB1 / TLR4 / NF-κB / TRPV1 signaling axis in the dorsal root ganglion, thereby reducing chronic pain after sepsis.
[0029] Compared with the prior art, the present invention has the following beneficial effects:
[0030] (1) Novel indication: This invention uses glycyrrhizic acid for chronic pain after sepsis, rather than for general inflammatory pain or neuropathic pain, which solves the problem of lack of specific drug intervention for long-term hyperalgesia in sepsis survivors.
[0031] (2) Complete Mechanism Chain: This invention constructs a continuous chain of evidence from sepsis, DRG macrophage activation, HMGB1 release, TLR4 / NF-κB signaling activation, TRPV1 upregulation to the formation of mechanical / thermal hyperalgesia, such as Figure 8 As shown.
[0032] (3) Clear technical effects: Glycyrrhizic acid can increase the mechanical pain threshold and prolong the latency of thermal stimulation response, and has a clear effect on improving mechanical hyperalgesia and thermal hyperalgesia.
[0033] (4) Not obvious: Although glycyrrhizic acid is known to have anti-inflammatory and HMGB1 inhibitory effects, the key pathology of chronic pain after sepsis is not simply systemic inflammation, but rather the local neuroimmune interaction of DRG and TRPV1-dependent pain sensitization; this combination of indications and pathways cannot be directly derived from existing technologies.
[0034] (5) Good translational foundation: Glycyrrhizic acid drugs already have a certain clinical application foundation. This invention provides new indications and mechanism positioning, which will help to carry out subsequent preclinical efficacy, safety and translational research.
[0035] (6) Advantages in clinical translation: Glycyrrhizic acid and its pharmaceutically acceptable salts have a clinical application basis, with clear safety data and industrialization foundation. They can significantly shorten the clinical development cycle for new indications of chronic pain after sepsis, and improve translation efficiency and industrial application value. Attached Figure Description
[0036] Figure 1 This study aimed to assess baseline pain levels in three groups of mice before surgery and monitor postoperative survival. (A) Preoperative pain behavioral experiments before CLP included the von Frey fiber test, acetone test, tailflick test (48℃, 50℃, 52℃), and hot plate test (50℃, 53℃, 56℃) to determine baseline pain levels in the NC, Sham, and CLP groups; (B) the timeline of the behavioral tests; and (C) the CLP modeling process. After CLP surgery, (D) weight change and (E) survival were monitored in the Sham and CLP groups for 7 consecutive days. ***p < 0.001, ns: no statistically significant difference.
[0037] Figure 2The study included behavioral and motor ability tests after CLP surgery; (A) open field test, with a schematic diagram of the movement trajectory (red dots represent the starting point, blue dots represent the ending point); (B) movement distance and (C) movement speed statistics in the open field test; (D) rotundus test, with a statistical graph showing the time it took for mice to maintain balance on the rotundus without falling; and (E) muscle strength test statistics. ***p < 0.001, ns: no statistical difference.
[0038] Figure 3 Hyperalgesia was induced in septicemia-surviving mice. The assays included: (A) von Frey fiber test, where values represented the withdrawal threshold; (B) acetone test, where values represented the cold pain response score; (CE) hot plate test (50°C, 53°C, and 56°C), where values represented the reaction time from the start of the stimulus to withdrawal; and (FH) tail flick test (48°C, 50°C, and 52°C), where values represented the reaction time from the start of the thermal stimulus to the flicking of the tail. ***p < 0.001; **p < 0.01; *p < 0.05.
[0039] Figure 4 This study analyzed the whole-genome expression of DRG in mice after CLP surgery. (A) Volcano plot of differentially expressed genes in DRG between the Sham and CLP groups: red dots represent upregulated genes, green dots represent downregulated genes, and blue dots represent genes with no significant difference. (B) KEGG functional enrichment analysis was performed to identify gene signaling pathways associated with differentially expressed genes. (C) GO analysis was conducted to identify biological processes related to pain and sepsis in upregulated genes. (D) Cluster heatmap analysis was performed to identify the expression levels of pain receptors and inflammatory factors related to pain perception in DRG between the Sham and CLP groups.
[0040] Figure 5 HMGB1 antagonism was used to improve pain in CLP mice. In the (AD) CLP group, mice were treated for 2 weeks with IL-1β antagonist (50 μg / time, intraperitoneal injection twice a week), IL-6 antagonist (1 mg / time, intraperitoneal injection every 2 days), TNF-α antagonist (25 mg / time, intraperitoneal injection every 2 days), and solvent control (physiological saline). The results of pain behavior tests were as follows: (A) acetone test, (B) von Frey fiber test, (C) tail flick test (48°C, 50°C and 52°C), (D) hot plate test (50°C, 53°C and 56°C), with n=6 in each group. Mice in the (EH)CLP group were treated with either the HMGB1 inhibitor glycyrrhizic acid (GA, 50 mg / kg / day, intraperitoneal injection for 7 days) or the solvent control (physiological saline). The results of pain behavior tests were as follows: (E) von Frey fiber test, (F) tail flick test, (G) hot plate test, and (H) acetone test. **p < 0.01, *p < 0.05.
[0041] Figure 6 HMGB1 regulates TRPV1 expression through the TLR4 / NF-κB signaling pathway; (A) Western blot analysis of protein expression levels of (B) TLR4, (C) p-NF-κB, (D) NF-κB, and (E) TRPV1 in the Sham, CLP+veh, CLP+GA, CLP+LPS-RS, and CLP+AA groups. The pain hyperalgesia threshold in CLP mice was assessed using pain behavior experiments: (F) von Frey filament test, (G) acetone test, (H) hot plate test (50°C, 53°C, and 56°C), and (I) tail flick test (48°C, 50°C, and 52°C). ***p < 0.001; **p < 0.01; *p < 0.05.
[0042] Figure 7 This is a schematic diagram illustrating the principle of the present invention.
[0043] Figure 8 This is a diagram illustrating the mechanism and comparison of the present invention. Detailed Implementation
[0044] The present invention will be further illustrated below with reference to specific embodiments. It should be understood that these embodiments are for illustrative purposes only and are not intended to limit the scope of the invention. Furthermore, it should be understood that after reading the teachings of this invention, those skilled in the art can make various alterations or modifications to the invention, and these equivalent forms also fall within the scope defined by the appended claims.
[0045] Example 1
[0046] I. Establishment of CLP sepsis mouse model and postoperative survival assessment:
[0047] To elucidate the mechanism by which sepsis induces chronic pain, a mouse model of sepsis was established using cecal ligation and perforation (CLP). Before CLP, mice were randomly divided into three groups: a blank control group (NC group), a sham-operated group (Sham group), and a CLP group. First, the baseline pain thresholds of the three groups were determined through behavioral tests. The evaluation indicators included: ① mechanical pain sensitivity (von Frey fiber test); ② thermal pain sensitivity (hot plate test: 50℃, 53℃, 56℃; hot tail flick test: 48℃, 50℃, 52℃); ③ cold pain sensitivity (acetone stimulation test). Baseline data showed no statistically significant differences in mechanical, thermal, and cold pain thresholds among the three groups (Figure 1A).
[0048] The experimental timing design is as follows ( Figure 1B): After the basic pain threshold was determined, Sham / CLP surgery was performed to model the mice. Then, the recovery of motor function was assessed 1 week after the operation. After confirming the recovery of motor function, dynamic monitoring of pain threshold was carried out for 4 weeks.
[0049] For detailed CLP surgical procedures, please refer to [link / reference]. Figure 1 C: Under aseptic conditions, the cecum was exposed, and double-line ligation was performed from the base of the cecum to the distal half. A 22G needle was used to puncture the distal cecum, and approximately two sesame seed-sized portions of intestinal contents were expelled into the abdominal cavity to create an infection environment. The abdomen was then closed layer by layer. Continuous monitoring of survival indicators for 7 days post-CLP showed that the CLP group exhibited significantly greater weight loss compared to the Sham group. Figure 1 D) and decreased survival rate Figure 1 E). By the observation endpoint (day 7 post-surgery), the cumulative mortality rate in the CLP group was 50% ( Figure 1 E), meeting the criteria for determining a moderate sepsis animal model.
[0050] II. Sepsis-surviving mice exhibited mechanical hyperalgesia and thermal hyperalgesia:
[0051] To rule out the potential impact of CLP surgical intervention on pain behavior assessment, a series of behavioral experiments were conducted on day 7 post-surgery to evaluate the recovery of motor function in surviving mice. The experiments included: ① voluntary activity assessment (open field test, ... Figure 2 AC); ② Motor coordination assessment (rotating bar test, Figure 2 D); ③ Muscle strength test ( Figure 2 E). Statistical analysis showed no statistically significant differences in motor function parameters among the NC group, Sham group, and CLP group (P>0.05), indicating that the motor function of the sepsis model mice had recovered after surgery.
[0052] Based on the confirmation of motor function recovery, the changes in pain threshold in the three groups of mice were dynamically monitored for four consecutive weeks. Figure 3 The von Frey test, an assessment of mechanical pain stimulation, showed that the CLP group exhibited a significant decrease in mechanical pain threshold from week 1 (CLP vs NC / Sham group, P<0.05), which progressively worsened over time, reaching a peak in weeks 2-3, indicating persistent mechanical hypersensitivity. Figure 3 A). Regarding thermal pain sensitivity testing: Hot plate tests (50℃, 53℃, and 56℃ stepped temperature tests) showed that the latency period for paw lifting and licking in the CLP group was significantly shortened from week 1. Figure 3 CE); The thermal tail flicking test (gradient stimulation at 48℃, 50℃, and 52℃) showed that the latency of the tail retraction response in the CLP group was significantly reduced compared with the control group, which was most obvious in the second week and this phenomenon continued until the fourth week. Figure 3The FH test confirmed the presence of a persistent thermal hyperalgesia phenotype. Notably, the acetone stimulation test did not detect a significant difference in cold pain thresholds among the three groups. Figure 3 B). The above results show that after the motor function of the sepsis model mice was restored, their mechanical hyperalgesia and thermal hyperalgesia phenotypes persisted for up to 4 weeks, indicating that a chronic pain model of sepsis was successfully established.
[0053] Example 2
[0054] The expression of DRG Trpv1 and Hmgb1 was upregulated in septic pain-sensitive mice:
[0055] To investigate the molecular mechanisms of chronic pain in sepsis, this study performed high-throughput RNA sequencing (RNA-seq) on DRG tissues from CLP and Sham mice. Genome-wide expression profiling analysis revealed 8,215 differentially expressed genes (DEGs) among 30,622 genes analyzed, of which 3,799 were upregulated and 4,416 were downregulated. Figure 4 A). Notably, the macrophage-specific marker MRC1 showed significantly high expression in the CLP group. Simultaneously, the pain receptor Trpv1, the pro-inflammatory cytokine Hmgb1, and the Tlr4 / Nf-κb signaling axis were all significantly upregulated in the DRG of the CLP group. Figure 4 A).
[0056] Pathway enrichment analysis using the Kyoto Encyclopedia of Genomes (KEGG) revealed that DEGs were primarily enriched in TRP channel receptor regulation, calcium ion signal transduction, neuroactive ligand-receptor interactions, and the Tlr4 / Nf-κb signaling pathway. Figure 4 B) suggests that the aforementioned signaling pathways may play a synergistic regulatory role in sepsis-related hyperalgesia. Further gene ontology (GO) functional annotation analysis revealed that DEGs were significantly enriched in biological processes such as pain perception, regulation of voltage-gated calcium channel activity, and neurotransmitter transport. Figure 4 C), these biological processes are closely related to pain signal transduction. Cluster heatmap visualization analysis confirmed that the expression levels of Hmgb1, Tlr4, Nf-κb, and Trpv1 were all upregulated in the CLP group ( Figure 4 D). Based on the results of multi-omics analysis, the HMGB1-TLR4-NF-κB inflammatory signaling axis and the TRPV1 channel may jointly participate in the chronic pain process of sepsis through molecular interaction mechanisms.
[0057] Example 3
[0058] HMGB1 promotes the development of chronic pain in sepsis:
[0059] Given the elevated expression levels of inflammatory cytokines HMGB1, TNF-α, IL-6, and IL-1β in the DRG of CLP mice, it is hypothesized that DRG macrophages may regulate sepsis-related pain by secreting specific inflammatory cytokines. To verify this hypothesis, CLP mice were first administered specific inhibitors or antagonists of the aforementioned inflammatory cytokines. Experimental data showed that the HMGB1 inhibitor glycyrrhizic acid (GA, 50 mg / kg) significantly improved pain behavior. In the von Frey test (mechanical pain test), GA treatment significantly increased the mechanical withdrawal threshold in CLP mice. Figure 5 E). Meanwhile, the tail-flick latency period ( Figure 5 F) and hot plate reaction time ( Figure 5 G) assays showed that GA treatment effectively reduced thermal hyperalgesia in CLP mice. Notably, this intervention did not significantly affect cold hyperalgesia. Figure 5 In contrast, IL-6, TNF-α, and IL-1β antagonists had no significant regulatory effect on pain behavior parameters in CLP mice. Figure 5 The results suggest that these inflammatory factors may not be directly involved in macrophage-mediated chronic pain in sepsis. These findings suggest that HMGB1 may play a key promoting role in chronic pain in sepsis.
[0060] Example 4
[0061] HMGB1 regulates TRPV1 expression through TLR4 / NF-κB signaling; blocking the TLR4 / NF-κB signaling pathway can alleviate chronic pain in sepsis.
[0062] Pharmacological interventions were used to intervene in the HMGB1 / TLR4 / NF-κB pathway, and changes in TRPV1 expression were detected. Western blot results showed that compared with the Sham group, the expression of TLR4, phosphorylated NF-κB (p-NF-κB), and TRPV1 proteins in the DRG of CLP group mice was significantly increased; and after intervention with the HMGB1 inhibitor GA (50 mg / kg), the TLR4 antagonist LPS-RS (Lipopolysaccharide from Rhodobacter sphaeroides, 0.5 mg / mL, 20 μL), and the NF-κB inhibitor alpha-lipoic acid (AA, 60 mg / kg), the expression of the above molecules was significantly inhibited. Figure 6(AE). Notably, GA, LPS-RS, and AA can inhibit the expression of HMGB1 / TLR4 / NF-κB, and when TLR4 / NF-κB is inhibited, the level of TRPV1 also decreases (TLR4 / NF-κB pathway inhibition can synchronously reduce TRPV1 expression), indicating that HMGB1 regulates TRPV1 expression through the TLR4 / NF-κB signaling pathway.
Claims
1. The use of glycyrrhizic acid, its pharmaceutically acceptable salts, esters, prodrugs, hydrates, solvates, crystal forms, pharmaceutical compositions, or preparations containing it as an active ingredient in the preparation of a medicine for the prevention, relief, and / or treatment of persistent chronic pain following sepsis.
2. The application according to claim 1, characterized in that, The chronic pain following sepsis includes one or more of the following: mechanical pain, thermal pain, cold pain, spontaneous pain, hyperalgesia, and abnormal pain.
3. The application according to claim 1, characterized in that, The drug works at least in part by modulating the HMGB1-associated inflammatory signaling network.
4. The application according to claim 1, characterized in that, The drug is used to reduce the expression levels of HMGB1, TLR4, phosphorylated NF-κB, and / or TRPV1 in the dorsal root ganglion.
5. The application according to claim 1, characterized in that, The drug is used to inhibit the activation of dorsal root ganglion macrophages and / or inhibit the expression, nucleocytoplasmic translocation, or extracellular release of HMGB1 from macrophages.
6. The application according to claim 1, characterized in that, The glycyrrhizic acid, in combination with other drugs, is used to prepare a drug for the prevention, relief, and / or treatment of persistent chronic pain following sepsis.
7. A pharmaceutical composition for the prevention, relief, and / or treatment of chronic pain following sepsis, characterized in that, The pharmaceutical composition comprises an effective amount of glycyrrhizic acid or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients.
8. The pharmaceutical composition according to claim 7, characterized in that, The dosage form of the pharmaceutical composition is selected from injection, lyophilized powder for injection, tablets, capsules, granules, oral liquid, sustained-release preparations, controlled-release preparations, gels, patches, liposome preparations, nanoparticle preparations, or microsphere preparations.
9. The pharmaceutical composition according to claim 7, characterized in that, The excipients are selected from one or more of the following: solvents, isotonic adjusters, pH adjusters, buffers, stabilizers, antioxidants, solubilizers, surfactants, fillers, disintegrants, binders, lubricants, penetration enhancers, or preservatives.
10. The use of a pharmaceutical composition according to any one of claims 7 to 9 in the preparation of a medicament for reducing the activation level of the HMGB1 / TLR4 / NF-κB / TRPV1 signaling axis in the dorsal root ganglion, characterized in that, Reduces chronic pain used for the prevention, relief, and / or treatment of sepsis.
